20 citations
,
August 2010 in “The Journal of Urology” Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
June 2014 in “The Journal of Urology” January 2009 in “프로그램북(구 초록집)” 22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
January 2026 in “Nature Reviews Urology”
5 citations
,
March 2010 in “Gynecologic and obstetric investigation” Cyproterone acetate implants were more effective at reducing facial hair and improving skin in severe hirsutism than oral treatment.
August 2011 in “SpringerReference” 2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
Cyproterone acetate with ethynyl estradiol significantly improved acne and seborrhea in women, but was less effective for hair loss and excessive hair growth.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
32 citations
,
February 2016 in “Journal of Dermatology” Dutasteride safely promotes hair growth and reduces hair loss, with mild side effects.
1 citations
,
June 2020 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with dutasteride may be a promising alternative treatment for hair loss.
August 2022 in “Dermatologic Therapy” The FDA did not approve a testosterone drug because of safety concerns.
8 citations
,
June 2017 in “Steroids” New chemical compounds were made that effectively block an enzyme linked to prostate growth.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
3 citations
,
October 1993 in “Endocrinology”
October 2025 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
February 2004 in “European Urology Supplements”
3 citations
,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.
11 citations
,
September 2006 in “European Urology Supplements” Combination therapy for BPH is cost-effective, especially for men with larger prostates.